CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
供者淋巴细胞输注在急性髓系白血病中的应用
英文原题：Donor lymphocyte infusion in Acute Myeloid Leukemia.
查看英文原题
Donor lymphocyte infusion in Acute Myeloid Leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
供者淋巴细胞输注（DLI）是异基因造血细胞移植（allo-HCT）后复发性血液系统恶性肿瘤管理中的一种重要治疗方式。供者T淋巴细胞可以以治疗性、抢先性或预防性方式使用，以试图激发移植物抗白血病（GVL）效应并清除残留病灶，甚至在高危情况下预防复发。然而，DLI并非没有并发症，尤其是移植物抗宿主病（GVHD）。迄今为止的数据仅限于回顾性研究和小型前瞻性研究。本综述总结了关于复发管理方法、DLI的剂量和时机、并发症以及潜在未来疗法的现有文献。
展开英文摘要原文
Donor lymphocyte infusion (DLI) is an important treatment modality in the management of relapsed hematological malignancies after allogeneic hematopoietic cell transplantation (allo-HCT). Donor T lymphocytes can be used in a therapeutic, pre-emptive or prophylactic manner in an attempt to stimulate a graft versus leukemia (GVL) effect and eradicate residual disease or even prevent relapse in a high-risk setting.
DLIs are not without complications, however, graft versus host disease (GVHD) in particular. Data to date is limited to retrospective and small prospective studies. This review summarizes the available literature on approaches to managing relapse, dosing and timing of DLI, complications and potential future therapies.
论文信息
- 作者
- Shah NA
- 单位
- Atrium Health, Levine Cancer Institute, USA. Electronic address: nilay.shah@atriumhealth.org.United States
- 文献类型
- 综述
- 期刊
- Best practice & research. Clinical haematology2023 Sep
- 原文标识
- PubMed 37612002 · DOI 10.1016/j.beha.2023.101484